GlassScriptPhysician profile
William N Farabaugh
NPI 1639167901
$10,039.65
in general payments reported to CMS, 2019-2025
56 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $601 · 2021: $1,913 · 2022: $1,611 · 2023: $2,094 · 2024: $1,375 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,788 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,788.31 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,308.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $940.86 | 2021-2024 | |
| Lilly USA, LLC | $825.50 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $806.74 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $799.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $577.10 | 2019-2025 | |
| Amgen INC. | $521.47 | 2019-2025 | Evenity, Prolia, Otezla |
| Biohaven Pharmaceuticals, INC. | $336.60 | 2021 | |
| Janssen Pharmaceuticals, INC | $324.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.53 | 2019-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $298.92 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.83 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $275.36 | 2019-2024 | Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $193.06 | 2021-2025 | |
| Abbott Laboratories | $176.58 | 2021-2025 | Freestyle Libre 3 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Farabaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.